André Robidoux

21.4k total citations · 8 hit papers
89 papers, 14.7k citations indexed

About

André Robidoux is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, André Robidoux has authored 89 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 51 papers in Cancer Research and 21 papers in Genetics. Recurrent topics in André Robidoux's work include Breast Cancer Treatment Studies (46 papers), Cancer Treatment and Pharmacology (27 papers) and HER2/EGFR in Cancer Research (25 papers). André Robidoux is often cited by papers focused on Breast Cancer Treatment Studies (46 papers), Cancer Treatment and Pharmacology (27 papers) and HER2/EGFR in Cancer Research (25 papers). André Robidoux collaborates with scholars based in Canada, United States and Belgium. André Robidoux's co-authors include Norman Wolmark, Joseph P. Costantino, D. Lawrence Wickerham, James N. Atkins, Bernard Fisher, Eleftherios P. Mamounas, Victor G. Vogel, Walter M. Cronin, Leslie G. Ford and Maureen Kavanah and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

André Robidoux

88 papers receiving 14.3k citations

Hit Papers

Tamoxifen for Prevention of Breast Cancer: Report of the ... 1998 2026 2007 2016 1998 2008 2010 2005 2011 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    1998 4.0k citations Joseph P. Costantino, D. Lawrence Wickerham et al. profile →
  2. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    2008 1.3k citations Priya Rastogi, Stewart Anderson et al. Journal of Clinical Oncology profile →
  3. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
    2010 1.3k citations Stewart Anderson, Thomas B. Julian et al. The Lancet Oncology profile →
  4. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    2005 937 citations Joseph P. Costantino, D. Lawrence Wickerham et al. profile →
  5. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
    2011 850 citations André Robidoux et al. The Lancet Oncology profile →
  6. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
    2007 773 citations Stewart Anderson, Thomas B. Julian et al. The Lancet Oncology profile →
  7. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    2006 722 citations Harry D. Bear, Stewart Anderson et al. Journal of Clinical Oncology profile →
  8. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
    2014 555 citations Mark Basik, David R. McCready et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
André Robidoux Canada 36 8.0k 7.7k 4.4k 4.1k 2.3k 89 14.7k
Nicole Rotmensz Italy 66 7.0k 0.9× 5.6k 0.7× 2.0k 0.5× 3.5k 0.8× 2.7k 1.2× 223 12.0k
Beat Thürlimann Switzerland 57 10.1k 1.3× 10.9k 1.4× 5.5k 1.2× 3.0k 0.7× 1.3k 0.6× 214 17.9k
Victor G. Vogel United States 49 5.5k 0.7× 8.0k 1.0× 6.7k 1.5× 2.3k 0.5× 871 0.4× 173 16.1k
James N. Atkins United States 47 4.4k 0.5× 8.3k 1.1× 3.9k 0.9× 2.0k 0.5× 1.4k 0.6× 107 14.4k
Lois E. Shepherd Canada 48 4.5k 0.6× 9.9k 1.3× 2.4k 0.6× 5.1k 1.2× 1.3k 0.6× 204 15.9k
Henning T. Mouridsen Denmark 57 6.7k 0.8× 8.0k 1.0× 2.5k 0.6× 3.0k 0.7× 2.5k 1.1× 243 14.1k
R. Jakesz Austria 58 5.2k 0.7× 7.2k 0.9× 3.0k 0.7× 1.5k 0.4× 2.0k 0.9× 337 12.2k
Marco Colleoni Italy 71 10.2k 1.3× 12.6k 1.6× 3.1k 0.7× 3.2k 0.8× 1.6k 0.7× 421 19.5k
Ivo A. Olivotto Canada 60 8.9k 1.1× 5.8k 0.8× 2.0k 0.4× 4.4k 1.1× 3.3k 1.5× 242 13.9k
Shinzaburo Noguchi Japan 64 5.2k 0.7× 6.1k 0.8× 2.5k 0.6× 2.1k 0.5× 1.5k 0.7× 389 13.7k

Countries citing papers authored by André Robidoux

Since Specialization
Citations

This map shows the geographic impact of André Robidoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Robidoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Robidoux more than expected).

Fields of papers citing papers by André Robidoux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André Robidoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Robidoux. The network helps show where André Robidoux may publish in the future.

Co-authorship network of co-authors of André Robidoux

This figure shows the co-authorship network connecting the top 25 collaborators of André Robidoux. A scholar is included among the top collaborators of André Robidoux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André Robidoux. André Robidoux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Geyer, Charles E., Hanna Bandos, Priya Rastogi, et al.. (2022). Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). Breast Cancer Research and Treatment. 193(3). 555–564. 4 indexed citations
2.
Swain, Sandra M., Gong Tang, Heather Ann Brauer, et al.. (2020). NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clinical Cancer Research. 26(16). 4233–4241. 18 indexed citations
3.
Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations
4.
Swain, Sandra M., Gong Tang, Peter C. Lucas, et al.. (2019). Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Breast Cancer Research and Treatment. 178(2). 389–399. 24 indexed citations
5.
6.
7.
Aebi, Stefan, Shari Gelber, Stewart Anderson, et al.. (2014). Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. The Lancet Oncology. 15(2). 156–163. 134 indexed citations
8.
Goodwin, Pamela J., Roanne Segal, Michael Vallis, et al.. (2014). Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. Journal of Clinical Oncology. 32(21). 2231–2239. 119 indexed citations
9.
Robidoux, André, Gong Tang, Priya Rastogi, et al.. (2013). Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet Oncology. 14(12). 1183–1192. 261 indexed citations
10.
Devriese, Lot A., Kevin M. Koch, Marja Mergui‐Roelvink, et al.. (2013). Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Investigational New Drugs. 32(3). 481–488. 41 indexed citations
11.
Bear, Harry D., Gong Tang, Priya Rastogi, et al.. (2013). Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. Obstetrical & Gynecological Survey. 68(3). 201–202. 64 indexed citations
12.
Bear, Harry D., Gong Tang, Priya Rastogi, et al.. (2012). Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. New England Journal of Medicine. 366(4). 310–320. 320 indexed citations
13.
Tan, Antoinette R., Marc Buyse, Priya Rastogi, et al.. (2012). NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).. Journal of Clinical Oncology. 30(15_suppl). 1025–1025. 3 indexed citations
14.
Aguilar‐Mahecha, Adriana, Josiane Lafleur, Carole Seguin‐Devaux, et al.. (2012). Q-CROC-03: A prospective biopsy driven clinical trial to study the mechanisms of resistance to chemotherapy in triple-negative breast cancer patients.. Journal of Clinical Oncology. 30(15_suppl). TPS1139–TPS1139. 1 indexed citations
15.
Vogel, Victor G., Joseph P. Costantino, D. Lawrence Wickerham, et al.. (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research. 3(6). 696–706. 438 indexed citations
16.
Mouridsen, Henning T., Per Eystein Lønning, Matthias W. Beckmann, et al.. (2010). Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy. 10(11). 1825–1836. 3 indexed citations
17.
Ghadirian, Parviz, et al.. (2009). Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity. Breast Cancer Research and Treatment. 117(2). 417–422. 18 indexed citations
18.
Lauzier, Sophie, Elizabeth Maunsell, Myrto Mondor, et al.. (2009). Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Research and Treatment. 120(3). 685–691. 47 indexed citations
19.
Hamm, John, John Wilson, Priya Rastogi, et al.. (2008). Gemcitabine/Epirubicin/Paclitaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group. Clinical Breast Cancer. 8(3). 257–263. 8 indexed citations
20.
Zhang, Shiyu, Catherine M. Phelan, François Rousseau, et al.. (2008). Frequency of the CHEK2 1100delC Mutation among Women with Breast Cancer: An International Study. Cancer Research. 68(7). 2154–2157. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole Rotmensz Breakdown of academic impact, for papers by Beat Thürlimann Breakdown of academic impact, for papers by Victor G. Vogel Breakdown of academic impact, for papers by James N. Atkins Breakdown of academic impact, for papers by Lois E. Shepherd Breakdown of academic impact, for papers by Henning T. Mouridsen Breakdown of academic impact, for papers by R. Jakesz Breakdown of academic impact, for papers by Marco Colleoni Breakdown of academic impact, for papers by Ivo A. Olivotto Breakdown of academic impact, for papers by Shinzaburo Noguchi
Rankless by CCL
2026